Centiva Capital LP acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,840 shares of the biotechnology company’s stock, valued at approximately $29,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Engineers Gate Manager LP purchased a new stake in Viking Therapeutics in the first quarter valued at about $37,000. Cetera Advisor Networks LLC acquired a new stake in Viking Therapeutics in the 2nd quarter worth approximately $36,000. PVG Asset Management Corp acquired a new stake in Viking Therapeutics in the 3rd quarter worth approximately $40,000. Virtu Financial LLC purchased a new position in shares of Viking Therapeutics in the third quarter worth $46,000. Finally, Envestnet Asset Management Inc. purchased a new position in shares of Viking Therapeutics in the second quarter worth $53,000. 34.71% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on VKTX shares. StockNews.com raised Viking Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 17th. Oppenheimer raised their price objective on Viking Therapeutics from $17.00 to $20.00 in a research note on Thursday. Maxim Group lifted their target price on Viking Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, December 19th. Raymond James raised their price target on shares of Viking Therapeutics from $11.00 to $12.00 and gave the stock an “outperform” rating in a research report on Thursday, February 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Viking Therapeutics in a report on Thursday, February 9th.
Viking Therapeutics Price Performance
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Read More
- Get a free copy of the StockNews.com research report on Viking Therapeutics (VKTX)
- MarketBeat Week in Review – 2/20 – 2/24
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating).
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
